Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.

Eliasson J, Hvistendahl MK, Freund N, Bolognani F, Meyer C, Jeppesen PB

JPEN. Journal of parenteral and enteral nutrition28 Mar 2022Cited by 19 (Europe PMC)

PMID35233802PMCIDPMC9545924DOI10.1002/jpen.2362PepBankPUB-35233802

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanNon-randomized trialSafety outcome
In adults with SBS, decreased GI stoma output occurred in 6 patients receiving apraglutide.
In plain wordsIn adults with SBS, reduced GI stoma output occurred in 6 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableDecreased GI stoma output
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with decreased gi stoma output
6 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
Common treatment-related adverse events were decreased gastrointestinal (GI) stoma output (n = 6),
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380201
02HumanNon-randomized trialSafety outcome
In adults with SBS, stoma complications occurred in 6 patients receiving apraglutide.
In plain wordsIn adults with SBS, stoma complications occurred in 6 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableStoma complications
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with stoma complications
6 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
stoma complications (n = 6)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380202
03HumanNon-randomized trialSafety outcome
In adults with SBS, GI stoma complications occurred in 5 patients receiving apraglutide.
In plain wordsIn adults with SBS, GI stoma complications occurred in 5 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableGI stoma complications
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with gi stoma complications
5 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
GI stoma complications (n = 5)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380203
04HumanNon-randomized trialSafety outcome
In adults with SBS, nausea occurred in 5 patients receiving apraglutide.
In plain wordsIn adults with SBS, nausea occurred in 5 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableNausea
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with nausea
5 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
nausea (n = 5)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380204
05HumanNon-randomized trialSafety outcome
In adults with SBS, flatulence occurred in 4 patients receiving apraglutide.
In plain wordsIn adults with SBS, gas occurred in 4 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableFlatulence
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with flatulence
4 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
flatulence (n = 4)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380205
06HumanNon-randomized trialSafety outcome
In adults with SBS, abnormal GI stoma output occurred in 4 patients receiving apraglutide.
In plain wordsIn adults with SBS, abnormal GI stoma output occurred in 4 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableAbnormal GI stoma output
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with abnormal gi stoma output
4 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
abnormal GI stoma output (n = 4)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380206
07HumanNon-randomized trialSafety outcome
In adults with SBS, polyuria occurred in 3 patients receiving apraglutide.
In plain wordsIn adults with SBS, excessive urination occurred in 3 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicablePolyuria
Study
n = 8
Analysis
Primary
Outcome group
Adverse events · Kidney and urinary
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with polyuria
3 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
polyuria (n = 3)
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380207
08HumanNon-randomized trialSafety outcome
In adults with SBS, abdominal pain occurred in 3 patients receiving apraglutide.
In plain wordsIn adults with SBS, abdominal pain occurred in 3 patients receiving apraglutide.
Peptide
Apraglutide
Outcome
Not applicableAbdominal pain
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with abdominal pain
3 patients
SBS-II and SBS-IF, 5 mg apraglutide
Source sentences
Summary
and abdominal pain (n = 3).
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380208
09HumanNon-randomized trialSafety outcome
In adults with SBS, one apraglutide-treated patient had treatment-related serious abdominal pain.
In plain wordsIn adults with SBS, one patient had serious abdominal pain related to apraglutide treatment.
Peptide
Apraglutide
Outcome
Not applicableSerious abdominal pain
Study
n = 8
Analysis
Primary
Outcome group
Gastrointestinal adverse events · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Patients with treatment-related serious adverse event (abdominal pain)
1 patient
8 patients treated with apraglutide
Source sentences
Summary
The only treatment-related serious adverse event (experienced in one patient) was abdominal pain.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380209
10HumanNon-randomized trialEfficacy outcome
In adults with SBS, apraglutide increased wet weight absorption by 741 g/day from baseline.
In plain wordsIn adults with SBS, apraglutide increased fluid absorption by 741 g/day from baseline.
Peptide
Apraglutide
Outcome
IncreaseWet weight absorption
Study
n = 8
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Adjusted mean wet weight absorption increase
741 g/day
change from baseline
Source sentences
Summary
Apraglutide significantly increased wet weight and energy absorption by an adjusted mean of 741 g/day (95% CI, 194 to 1287; P = 0.015) and 1095 kJ/day (95% CI, 196 to 1994; P = 0.024), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380210
11HumanNon-randomized trialEfficacy outcome
In adults with SBS, apraglutide increased energy absorption by 1095 kJ/day from baseline.
In plain wordsIn adults with SBS, apraglutide increased energy absorption by 1095 kJ/day from baseline.
Peptide
Apraglutide
Outcome
IncreaseEnergy absorption
Study
n = 8
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Adjusted mean energy absorption increase
1095 kJ/day
change from baseline
Source sentences
Summary
Apraglutide significantly increased wet weight and energy absorption by an adjusted mean of 741 g/day (95% CI, 194 to 1287; P = 0.015) and 1095 kJ/day (95% CI, 196 to 1994; P = 0.024), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380211
12HumanNon-randomized trialEfficacy outcome
In adults with SBS, apraglutide increased sodium absorption by 38 mmol/day from baseline.
In plain wordsIn adults with SBS, apraglutide increased sodium absorption by 38 mmol/day from baseline.
Peptide
Apraglutide
Outcome
IncreaseSodium absorption
Study
n = 8
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Adjusted mean sodium absorption increase
38 mmol/day
change from baseline
Source sentences
Summary
Sodium and potassium absorption significantly increased by an adjusted mean of 38 mmol/day (95% CI, 3 to 74; P = 0.039) and 18 mmol/day (95% CI, 4 to 32; P = 0.020), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380212
13HumanNon-randomized trialEfficacy outcome
In adults with SBS, apraglutide increased potassium absorption by 18 mmol/day from baseline.
In plain wordsIn adults with SBS, apraglutide increased potassium absorption by 18 mmol/day from baseline.
Peptide
Apraglutide
Outcome
IncreasePotassium absorption
Study
n = 8
Analysis
Secondary
Outcome group
Gastrointestinal protection · Gastrointestinal
Studied dose
5 mg once weekly · subcutaneous · 4 weeksAs given in this study (human).
Measurements
Adjusted mean potassium absorption increase
18 mmol/day
change from baseline
Source sentences
Summary
Sodium and potassium absorption significantly increased by an adjusted mean of 38 mmol/day (95% CI, 3 to 74; P = 0.039) and 18 mmol/day (95% CI, 4 to 32; P = 0.020), respectively.
1 context sentence(design, population, supporting numbers)
Summary · context
In this open-label, phase 1 and 2 trial, adult patients with SBS-II (n = 4) or SBS-IF (n = 4) and a fecal output of ≥1500 g/day received once-weekly subcutaneous 5 mg apraglutide for 4 weeks.
Report a problemFND-3523380213

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Apraglutide, a novel once-weekly glucagon-like peptide-2 analog, improves intestinal fluid and energy absorption in patients with short bowel syndrome: An open-label phase 1 and 2 metabolic balance trial.

Summary

Results from this study13

Version history

Subjects

Publication types

MeSH terms

Keywords